UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

Neuro-oncology (Charlottesville, Va.), 2010-10, Vol.12 (10), p.1061-1070

2010

Volltextzugriff (PDF)

Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials

Drug design, development and therapy, 2017-01, Vol.11, p.1719-1728

2017

Volltextzugriff (PDF)

Azacitidine Induces Demethylation of the Epstein-Barr Virus Genome in Tumors

Journal of clinical oncology, 2004-04, Vol.22 (8), p.1373-1381

2004

Volltextzugriff (PDF)

Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: A Phase I study of ZYC101

Clinical cancer research, 2002-05, Vol.8 (5), p.1028-1037

2002

Volltextzugriff (PDF)

5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results

European journal of cancer supplements, 2009, Vol.7 (2), p.266-267

2009

Volltextzugriff (PDF)

Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma

Annals of oncology, 2002-04, Vol.13 (4), p.576-581

2002

Volltextzugriff (PDF)

Improved Transfusion Independence Rates for Momelotinib versus Ruxolitinib in Anaemic Jaki Naive Myelofibrosis Patients Independent of Baseline Platelet or Transfusion Status

BRITISH JOURNAL OF HAEMATOLOGY, 2022, Vol.197, p.81

2022

Volltextzugriff (PDF)

Improved transfusion independence rates for momelotinib versus ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status

JOURNAL OF CLINICAL ONCOLOGY, 2021, Vol.39 (15_suppl), p.e19039-e19039

2021

Volltextzugriff (PDF)

The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer

International journal of radiation oncology, biology, physics, 1999-04, Vol.44 (1), p.127-131

1999

Volltextzugriff (PDF)

SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.3126

2009

Volltextzugriff (PDF)

A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.1017-1017

2009

Volltextzugriff (PDF)

Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.1003-1003

2009

Volltextzugriff (PDF)

The restricted cellular host range of human herpesvirus 8

AIDS (London), 2000-06, Vol.14 (9), p.1123-1133

2000

Volltextzugriff (PDF)

A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.33

2009

Volltextzugriff (PDF)

Clinical pharmacokinetics of erlotinib (E) in glioblastoma multiforme (GBM) patients and its implication for dosing

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.2010-2010

2006

Volltextzugriff (PDF)

P-492 A multicenter, open-label, phase Ilia trial of erlotinib in patients with advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2005-07, Vol.49, p.S246-S246

2005

Volltextzugriff (PDF)

Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naive Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, Vol.21, p.S353

2021

Volltextzugriff (PDF)

Anal cancer: an HIV-associated cancer

Hematology/oncology clinics of North America, 2003-06, Vol.17 (3), p.859-872

2003

Volltextzugriff (PDF)

Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.1036-1036

2008

Volltextzugriff (PDF)

Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.1507-1507

2005

Volltextzugriff (PDF)

Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.1555-1555

2004

Volltextzugriff (PDF)

Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.1555-1555

2004

Volltextzugriff (PDF)

Advances and future challenges in non-Hodgkinʼs lymphoma

Current opinion in oncology, 1998-09, Vol.10 (5), p.422-428

1998

Volltextzugriff (PDF)

Intra-abdominal desmoplastic small round-cell tumor: expansion of the pathologic profile

Modern pathology, 1996-06, Vol.9 (6), p.703

1996

Volltextzugriff (PDF)

Altered clinical course of malignant melanoma in HIV-positive patients

Archives of dermatology (1960), 2002-06, Vol.138 (6), p.765

2002

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(25)
Tagungsberichte
(3)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Humans
(11)
Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Oncology
(8)
Adult
(7)
Aged
(6)
Biological And Medical Sciences
(6)
Male
(6)
Middle Aged
(6)
Female
(5)
Medical Sciences
(5)
Treatment Outcome
(4)
Aged, 80 And Over
(3)
Aids/hiv
(3)
Medicin Och Hälsovetenskap
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Anus Neoplasms - Drug Therapy
(2)
Anus Neoplasms - Immunology
(2)
Anus Neoplasms - Virology
(2)
Base Sequence
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials

Azacitidine Induces Demethylation of the Epstein-Barr Virus Genome in Tumors

Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: A Phase I study of ZYC101

5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results

Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma

Improved Transfusion Independence Rates for Momelotinib versus Ruxolitinib in Anaemic Jaki Naive Myelofibrosis Patients Independent of Baseline Platelet or Transfusion Status

Improved transfusion independence rates for momelotinib versus ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status

The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer

SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results

A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results

Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1)

The restricted cellular host range of human herpesvirus 8

A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer

Clinical pharmacokinetics of erlotinib (E) in glioblastoma multiforme (GBM) patients and its implication for dosing

P-492 A multicenter, open-label, phase Ilia trial of erlotinib in patients with advanced non-small cell lung cancer

Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naive Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status

Anal cancer: an HIV-associated cancer

Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC)

Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome

Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial

Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial

Advances and future challenges in non-Hodgkinʼs lymphoma

Intra-abdominal desmoplastic small round-cell tumor: expansion of the pathologic profile

Altered clinical course of malignant melanoma in HIV-positive patients

Suchergebnisse filtern